08:00-08:30
Registration

08:30-10:00

Session 1: Molecular Biology and Mycobacterial Evolution

Exploring the molecular underpinnings of mycobacterial evolution, this session connects genetic diversity, functional biology, and host-pathogen interaction to inform future TB research and innovation

Chairs: Mireia Coscolla, Sébastien Gagneux

08:30  Christophe Sola, Université Paris-Saclay IAME (INSERM-Université Paris-Cité, Université Sorbonne Paris-Nord)

GL03: An Interdisciplinary Approach to Tuberculosis Evolutionary History

​

09:00  Paula Ruiz Rodriguez, University of Valencia

OR01: Complementary gene loss and sequence diversification shape host adaptation in the Mycobacterium tuberculosis complex 

​

09:15  Mireia Coscolla, University of Valencia

OR02: Structural remodeling in a closed pangenome shapes evolution in the Mycobacterium tuberculosis complex

​

09:30  Alina Minias, Institute of Medical Biology Polish Academy of Sciences

OR03: Evolutionary patterns guiding identification of druggable and resistance-linked sites in Mycobacterium tuberculosis 

​​

09:45  Luke Harrison, Research Institute of the McGill University Health Centre

OR04: Patterns of substitution rate variation across the Mycobacterium tuberculosis complex ​​​​​

10:00-10:30
Coffee Break

10:30-11:45
Session 2: TB Short Regimens in trials

How short can you go? This session examines the latest clinical trials testing the limits of tuberculosis treatment shortening, balancing efficacy, safety, and implementation feasibility

​

Chairs: Francesca Saluzzo, Lorenzo Guglielmetti

10:30  Jodie Schildkraut, Radboud University Medical Center

GL04: How Short Can We Go? Evidence and Innovation in TB Treatment

​​

11:00  Andrea Muscetti, Università Vita e Salute San Raffaele, Milano

OR05: Implementation of standardised EUCAST-aligned MIC testing in the PARADIGM4TB trial

​

11:15  Andrei Gabrielian OCICB NIAID NIH

OR06: Tuberculosis missed by initial bacteriological tests is a distinct clinical subgroup

​

11:30  Annelies Van Rie, University of Antwerp

OR07: Economic evaluation of Whole Genome Sequencing Guided Treatment for Rifampicin-Resistant Tuberculosis - a within trial analysis ​

​​​​​

11:45-12:30
Poster pitches - Session 1
Chair: Leen Rigouts

1 minute per poster (23 posters)​​

12:30-13:30
Lunch

13:30-14:45
Poster Session 1 

All posters with uneven numbers (P001, P003 etc)

14:45-16:00
Session 3: Exploring new  strategies for diagnosis of TB and other pathogens 

This session explores innovative diagnostic strategies for tuberculosis and nontuberculous mycobacteria, emphasizing the challenges of maintaining high positive predictive value in low-incidence resource-rich European settings.​

​

Chairs: Erik Svensson, Tim Walker

​

14:45  Claudia Denkinger, University of Heidelberg
GL05:  Alternative diagnostic approach and applicability in low incidence contests

​​

15:15  Dag Harmsen, University Münster, Ridom GmbH

OR08: Evaluation of a GUI-pipeline with integrated database for storing all results for detection of resistance to anti-tuberculous drugs from WGS data 

​

15:30  Emilyn Costa Conceicao, Stellenbosch University

OR09: Real-time culture-based whole-genome sequencing for clinical management of rifampicin-resistant tuberculosis–insights from the PARR-TB implementation research study in South Africa

​​​

15:45  Teunie Westera, Bilthoven Biologicals BV

OR10: Distinct On/Off Induration Profile of rdESAT-6/rCFP-10 in Pooled TESEC Trials​​​

​​​​​

16:00-16:30
Coffee Break

16:30-18:15
Session 4: New Diagnostics for MDR-TB 

This session highlights advances in molecular and phenotypic diagnostics for multidrug-resistant tuberculosis, focusing on tools that enable faster, more precise detection to guide effective treatment

​

Chairs: Stefan Niemann, Sofie Braet

16:30  Andrea M Cabibbe, IRCCS San Raffaele Scientific Institute, Milan

GL06:  Direct sequencing of Mycobacterium tuberculosis from sputum: how far are we?

​​

17:00  Vincent Rennie, University of Antwerp

OR11: Whole-genome sequencing for drug resistance and transmission inference: simulating a combined direct-from-sputum and culture-based sequencing approach.

​

17:15  Ruan Spies, University of Oxford

OR12: Undetected isoniazid resistance leads to rifampicin-resistant tuberculosis

​

17:30  Roya Akar, Public Health Agency of Sweden, Karolinska Institutet, Solna, 

OR13: Multi-laboratory study of meropenem–clavulanic acid minimum inhibitory concentration distributions for the Mycobacterium tuberculosis complex determined by broth microdilution

​​​​​

17:45  Elisa Nemes, University of Cape Town

GL07: Host biomarkers for childhood tuberculosis​​

​​

​​

18:30
Guided tour 

Departure from Chamber of commerce​

20:00
Traditional dinner

@ San Matteo Church, Vicolo San Matteo 4​